John Thomas Sells 10,000 Shares of Genelux (NASDAQ:GNLX) Stock

Genelux Corporation (NASDAQ:GNLX) Director John Thomas sold 10,000 shares of the firm’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $5.00, for a total value of $50,000.00. Following the transaction, the director owned 492,784 shares of the company’s stock, valued at $2,463,920. This trade represents a 1.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Genelux Stock Down 3.5%

NASDAQ:GNLX traded down $0.17 on Tuesday, reaching $4.73. 224,242 shares of the company’s stock were exchanged, compared to its average volume of 309,396. Genelux Corporation has a 52-week low of $1.99 and a 52-week high of $8.53. The business has a fifty day moving average of $5.70 and a 200-day moving average of $4.08.

Genelux (NASDAQ:GNLX) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.02. Analysts predict that Genelux Corporation will post -0.88 EPS for the current year.

Hedge Funds Weigh In On Genelux

A number of institutional investors and hedge funds have recently modified their holdings of GNLX. Creative Planning raised its stake in Genelux by 4.7% in the third quarter. Creative Planning now owns 46,108 shares of the company’s stock valued at $194,000 after buying an additional 2,084 shares in the last quarter. Raymond James Financial Inc. lifted its holdings in Genelux by 22.6% during the 2nd quarter. Raymond James Financial Inc. now owns 28,933 shares of the company’s stock worth $83,000 after buying an additional 5,333 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Genelux by 1.8% during the 2nd quarter. Geode Capital Management LLC now owns 318,825 shares of the company’s stock worth $915,000 after acquiring an additional 5,596 shares in the last quarter. 5T Wealth LLC increased its holdings in shares of Genelux by 33.9% in the 3rd quarter. 5T Wealth LLC now owns 24,101 shares of the company’s stock valued at $101,000 after acquiring an additional 6,100 shares during the last quarter. Finally, LifeSteps Financial Inc. increased its holdings in shares of Genelux by 8.2% in the 3rd quarter. LifeSteps Financial Inc. now owns 105,171 shares of the company’s stock valued at $442,000 after acquiring an additional 7,952 shares during the last quarter. Institutional investors and hedge funds own 37.33% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on GNLX. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Genelux in a research report on Wednesday, October 8th. Maxim Group set a $20.00 target price on Genelux in a research note on Tuesday, October 21st. Loop Capital set a $16.00 price target on Genelux in a report on Tuesday, October 21st. Finally, Lake Street Capital assumed coverage on Genelux in a research report on Tuesday, October 21st. They issued a “buy” rating and a $16.00 price target on the stock. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Genelux currently has a consensus rating of “Moderate Buy” and an average price target of $21.00.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.